(NASDAQ: OABI) Omniab's forecast annual revenue growth rate of 12.89% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.77%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.78%.
Omniab's revenue in 2026 is $38,457,000.On average, 9 Wall Street analysts forecast OABI's revenue for 2026 to be $5,205,121,639, with the lowest OABI revenue forecast at $4,701,925,471, and the highest OABI revenue forecast at $5,560,019,600. On average, 8 Wall Street analysts forecast OABI's revenue for 2027 to be $6,449,663,446, with the lowest OABI revenue forecast at $4,274,477,701, and the highest OABI revenue forecast at $10,380,874,417.
In 2028, OABI is forecast to generate $8,124,851,611 in revenue, with the lowest revenue forecast at $5,556,821,012 and the highest revenue forecast at $10,980,900,590.